According to FutureWise analysis, the Alcoholic Hepatitis Therapeutics market was estimated to be US$0.92 billion in 2025 and is expected to reach US$1.38 billion by 2033, at a CAGR of 5.2%. The alcoholic hepatitis therapeutics market is growing primarily due to the increasing prevalence of alcohol use disorders globally and an enhanced awareness of liver diseases among healthcare professionals and patients. This growth highlights the urgent need for effective treatment options, as alcoholic hepatitis is a significant cause of liver-related mortality and currently has limited therapeutic alternatives available in the market.

The growth in this area is driven by the rising incidence of alcohol-related liver disorders and a growing awareness of the importance of early diagnosis and intervention. Improvements in targeted therapies and the development of biologics are also contributing to better treatment outcomes. Additionally, increased investments in healthcare for managing liver diseases are further propelling market expansion.

In May 2024, DURECT Corporation received FDA Breakthrough Therapy designation for larsucosterol, highlighting its potential in treating alcohol-associated hepatitis. The FEMTAH trial demonstrates that fecal microbiota therapy is a safe and effective treatment option for patients who cannot use steroids, providing a novel approach.

Alcoholic hepatitis (AH) is an inflammation of the liver caused by excessive alcohol consumption. It is characterized by the rapid onset of jaundice, malaise, anorexia, tender enlargement of the liver (hepatomegaly), and features of systemic inflammatory response syndrome (SIRS). AH typically occurs in individuals who have been heavy drinkers for many years. Patients with alcoholic hepatitis are often seriously ill and have a high risk of nutritional deficiencies, acute kidney injury (AKI), infections, and the development of multiorgan failure (MOF). In the United States, approximately two-thirds of adults consume alcohol each year, and around 7.4% identify as heavy drinkers, meeting the criteria for alcoholism. However, only a small percentage of heavy drinkers will develop alcoholic liver disease (ALD), likely due to a combination of environmental and genetic factors. To improve clinical outcomes for patients with severe alcoholic hepatitis, it is essential to accurately identify potential complications and understand the fundamental mechanisms behind alcohol-induced liver damage.

Corticosteroids are the current primary treatment for severe alcoholic hepatitis (defined as DF ≥ 32, MELD ≥ 21, or presence of hepatic encephalopathy) in patients without contraindications for steroid treatment. Corticosteroids alter the balance of cytokines, reducing pro-inflammatory cytokines, including tumor necrosis factor-alpha (TNF-α), and increasing anti-inflammatory cytokines, such as interleukin-10. Corticosteroids have potent anti-inflammatory effects. In cases of severe alcoholic hepatitis, there is significant inflammation in the liver. Corticosteroids can help reduce this inflammation, which may help improve liver function. They also have immunosuppressive properties, which can be beneficial in cases where the immune system is overactive and contributes to liver damage.

 FutureWise Market Research has released a report that provides an in-depth analysis of the Alcoholic Hepatitis Therapeutics Market trends that shall affect the overall market growth.

Request a Free Sample @

https://www.futurewiseresearch.com/contact.aspx?rpt=11007&type=requestsample

By Drug Type

• Monoclonal antibodies
• Caspase protease inhibitor
• Corticosteroids
• Hemorheologic agents
• Anabolic steroids
• Hepatotropic hormones
• Sulfhydryl agents
• Other Drug Types

By Application

• Mild Disease
• Severe Disease

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies 

By Region

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa

Here’s a regional view of where the most progress is happening:

North America 

• North America remains at the forefront of the market for alcoholic hepatitis therapeutics.
• The region contributes the largest share of global revenue, driven by:
• Enhanced healthcare infrastructure
• There is increased awareness and higher rates of diagnosis.
• There is a strong adoption of emerging therapies, which include steroids, biologics, and novel approaches such as microbiota therapy.

Asia-Pacific

Key growth drivers include:

• There is a growing trend in alcohol consumption, which is associated with a rising incidence of alcoholic hepatitis. Enhancing access to healthcare and improving infrastructure.

Competitive Landscape in Alcoholic Hepatitis Therapeutics Market:

• Alkermes Inc.
• Alfact Innovation
• Conatus Pharmaceuticals Inc.
• Dainippon sumitomo pharma Co. ltd.
• Generon Corporation Ltd.
• Immuron limited
• Lupin Laboratories Ltd.
• Intercept Pharmaceuticals Inc.
• Teva Pharmaceuticals Ltd.
• Sanofi-Aventis
• Siesta Pharmaceuticals
• Gilead Sciences Inc
• ABBVIE Inc
• Novartis
• Roche

Recent developments by key players in the Alcoholic Hepatitis Therapeutics Market:

Novartis

• Canakinumab, a groundbreaking IL-1β monoclonal antibody developed by Novartis, is making waves in the fight against alcoholic hepatitis. Currently under investigation in the Phase II ISAIAH trial, this exciting randomized, placebo-controlled study is taking place in various centers across the U.K. The trial aims to uncover promising histological improvements in liver biopsies after just 28 days. Stay tuned as researchers work towards a potential breakthrough in treatment!

Teva Pharmaceuticals Ltd.

• Teva continues to strengthen its presence in corticosteroid-based therapies through enhanced generic distribution, particularly in India and Brazil, thereby reinforcing its footprint in emerging markets.
• Although specific new pipeline candidates are not emphasized, Teva remains listed among major players, alongside innovators, highlighting its ongoing involvement and potential future activity.

Sanofi-Aventis

• Sanofi consistently ranks as a key competitor in the treatment of alcoholic hepatitis, maintaining its focus on research and development of immunologic and anti-inflammatory agents. However, no new candidates have been publicly disclosed this year.
• Collaborating with other pharmaceutical leaders underscores a continued commitment to developing a diverse pipeline of therapies for liver disease.

Buy now the latest version of this report: https://www.futurewiseresearch.com/checkout.aspx?ReportId=11007&license=multi

**Objectives of this Study: **

1. To provide a comprehensive analysis of the Alcoholic Hepatitis Therapeutics Market By Drug Type, By Application, By Distribution Channel and By Region.
2. To offer detailed insights into factors such as drivers, restraints, trends, and opportunities, as well as segmental and regional influences on market growth.
3. To evaluate current market trends and forecast micro-markets, presenting overall market projections in the form of data sets and PowerPoint presentations.
4. To predict the market size in key regions, including North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.

                                                                                                                
Flexible Delivery Model:

• We have a flexible delivery model and you can suggest changes in the scope/table of contents as per your requirement
• The customization services offered are free of charge with the purchase of any license of the report.
• You can directly share your requirements/changes to the current table of contents to: sales@futurewiseresearch.com